Successful treatment of refractory bronchioloalveolar carcinoma with S-1 (oral fluoropyrimidine)

Respirology. 2009 Jul;14(5):771-2. doi: 10.1111/j.1440-1843.2009.01546.x.

Abstract

Bronchioloalveolar carcinoma (BAC) is a distinct subtype of non-small cell lung cancer for which there is no optimal therapy for non-resectable or recurrent disease. This report describes a patient with BAC refractory to conventional chemotherapy but with a partial response to S-1, oral fluoropyrimidine, resulting in symptom improvement and weaning from oxygen supplementation. Our observation suggests that S-1 is a novel option for the treatment of advanced BAC.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma, Bronchiolo-Alveolar / drug therapy*
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Drug Combinations
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Middle Aged
  • Oxonic Acid / therapeutic use*
  • Tegafur / therapeutic use*
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Drug Combinations
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid